1-14 of 14
Anna Moseley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Anna Moseley, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, Megan Othus
Journal: Blood
Blood (2022) 140 (Supplement 1): 8932–8933.
https://doi.org/10.1182/blood-2022-170376
Published: 2022
Journal Articles

Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Derek Stirewalt, Megan Othus, Jasmine Naru, Jacob J Kennedy, Era L Pogosova-Agadjanyan, Frederick R. Appelbaum, Lan Beppu, Thomas R. Chauncey, Jeffrey Delrow, Harry P. Erba, Phillip R Gafken, John E. Godwin, Matthew Fitzgibbon, Xing Hua, Isaac C. Jenkins, Min Fang, Richard G Ivey, ChenWei Lin, Travis D Lorentzen, Anna Moseley, Jerald P. Radich, Uliana J Voytovich, Pei Wang, Jeffrey Whiteaker, Cheryl L Willman, Feinan Wu, Soheil Meshinchi, Amanda G Paulovich
Journal: Blood
Blood (2021) 138 (Supplement 1): 799.
https://doi.org/10.1182/blood-2021-151678
Published: 2021
Journal Articles

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Brent Wood, Jae H Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 3397.
https://doi.org/10.1182/blood-2021-145529
Published: 2021
Journal Articles

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Jasmine Naru, Megan Othus, ChenWei Lin, Anna Moseley, Cheryl L Willman, Era L Pogosova-Agadjanyan, Feinan Wu, Frederick R. Appelbaum, Harry P. Erba, Isaac C. Jenkins, Jacob J Kennedy, Jeffrey Delrow, Jeffrey Whiteaker, Jerald P. Radich, John E. Godwin, Lan Beppu, Matthew Fitzgibbon, Min Fang, Pei Wang, Phillip R Gafken, Richard G Ivey, Soheil Meshinchi, Thomas R. Chauncey, Travis D Lorentzen, Uliana J Voytovich, Amanda G Paulovich, Derek Stirewalt
Journal: Blood
Blood (2021) 138 (Supplement 1): 522.
https://doi.org/10.1182/blood-2021-151246
Published: 2021
Journal Articles

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902)

Deborah M. Stephens, Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch, Alexey V. Danilov, David Ng, Anthony R. Mato, Danielle M. Brander, Megan Othus, Steven Coutre, Susan M. O'Brien, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 2630.
https://doi.org/10.1182/blood-2021-144780
Published: 2021
Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Era L Pogosova-Agadjanyan, BS, Anna Moseley, M.S., Megan Othus, PhD, Frederick R. Appelbaum, MD, Thomas R. Chauncey, MD PhD, I-Ming L. Chen, DVM, MS, Harry P. Erba, MD PhD, John E. Godwin, MD, Isaac C. Jenkins, MS, Min Fang, MD PhD, Mike Huynh, Kenneth J Kopecky, Alan F. List, MD, Jasmine Naru, PhD, Jerald P. Radich, MD, Emily Stevens, MD PhD, Brooke E Willborg, BS, Cheryl L. Willman, MD, Brent L Wood, MD PhD, Qing Zhang, Soheil Meshinchi, MD PhD, Derek Stirewalt, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2691.
https://doi.org/10.1182/blood-2019-124529
Published: 2019
Journal Articles

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Anjali S. Advani, MD, Anna Moseley, M.S., Michaela Liedtke, MD, Margaret R O'Donnell, MD, Ibrahim Aldoss, MD, Martha P. Mims, MD PhD, Kristen Marie O'Dwyer, MD, Megan Othus, PhD, Harry P. Erba, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 227.
https://doi.org/10.1182/blood-2019-125340
Published: 2019
Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3905.
https://doi.org/10.1182/blood-2019-124320
Published: 2019
Journal Articles

Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia

Anjali S. Advani, MD, Anna Moseley, M.S., Kristen Marie O'Dwyer, MD, Brent Wood, MDPhD, Min Fang, MDPhD, Matthew J. Wieduwilt, MD PhD, Ibrahim Aldoss, MD, Jae H. Park, MD, Rebecca Klisovic, MD, Maria R. Baer, MD, Wendy Stock, MD, Rupali Bhave, MD, Megan Othus, PhD, Mark R. Litzow, MD, Richard M. Stone, MD, Harry P. Erba, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 33.
https://doi.org/10.1182/blood-2018-99-111992
Published: 2018
Journal Articles

A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312)

Anjali S. Advani, MD, Anna Moseley, Michaela Liedtke, MD, Margaret O'Donnell, MD, Megan Othus, PhD, Martha P. Mims, MD PhD, Kristen O'Dwyer, MD, Harry P. Erba, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1634.
https://doi.org/10.1182/blood.V128.22.1634.1634
Published: 2016
Journal Articles

Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat

John M. Pagel, MD PhD, Megan Othus, PhD, Guillermo Garcia-Manero, MD, Min Fang, Jerald P. Radich, MD, David A. Rizzieri, MD, Guido Marcucci, MD, Stephen A. Strickland, Mark Litzow, MD, Mary Lynn Savoie, MD FRCPC, Stephen R. Spellman, MBS, Dennis L. Confer, MD, Jeffrey Chell, MD, Maria Brown, Bruno C. Medeiros, MD, Mikkael A. Sekeres, MD MS, Tara L. Lin, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard A. Larson, MD, Richard M. Stone, MD, David F. Claxton, MD, James Essell, MD, Selina Luger, MD, Sanjay R. Mohan, MD, Anna Moseley, Harry P. Erba, MD PhD, Frederick R. Appelbaum, MD
Journal: Blood
Blood (2016) 128 (22): 1166.
https://doi.org/10.1182/blood.V128.22.1166.1166
Published: 2016
Journal Articles

ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial

Jeffrey E. Lancet, MD, Anna Moseley, Rami S Komrokji, MD, Steven E. Coutre, MD, Daniel J. DeAngelo, MD PhD, Martin S. Tallman, MD, Mark Litzow, MD, Megan Othus, Frederick R Appelbaum, MD
Journal: Blood
Blood (2016) 128 (22): 896.
https://doi.org/10.1182/blood.V128.22.896.896
Published: 2016
Journal Articles

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Megan Othus, John M. Pagel, MD PhD, Jerald P. Radich, Min Fang, David A Rizzieri, MD, Guido Marcucci, MD, Stephen A. Strickland, Mark Litzow, MD, Mary Lynn Savoie, MD, Bruno C. Medeiros, MD, Mikkael A. Sekeres, MD MS, Tara L. Lin, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard A. Larson, MD, Richard M. Stone, MD, David F. Claxton, MD, James Essell, MD, Selina Luger, MD, Sanjay R. Mohan, MD, Anna Moseley, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD
Journal: Blood
Blood (2016) 128 (22): 901.
https://doi.org/10.1182/blood.V128.22.901.901
Published: 2016
Journal Articles

Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report

Era L. Pogosova-Agadjanyan, Anna Moseley, Brent L. Wood, MD PhD, Frederick R. Appelbaum, Thomas Chauncey, I-Ming L. Chen, DVM, MS, Harry P. Erba, MD PhD, John E. Godwin, Min Fang, Kenneth J. Kopecky, Alan F. List, Megan Othus, Jerald P. Radich, Cheryl L. Willman, Soheil Meshinchi, Derek L. Stirewalt
Journal: Blood
Blood (2016) 128 (22): 2890.
https://doi.org/10.1182/blood.V128.22.2890.2890
Published: 2016